CD8A and cancer: Therapeutic delivery of IL-2, such as by systemic IL-2C treatment using the S4B6 clone and 1–2 μg of recombinant IL-2 has seen increasing use in experimental models to modulate CD8 T cell and NK cell populations in vivo to improve responses against pathogens and cancers [43].